The Additional Hetero Ring Is Five-membered Having Ring Nitrogen Patents (Class 514/254.01)
  • Publication number: 20040259843
    Abstract: The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
    Type: Application
    Filed: February 27, 2004
    Publication date: December 23, 2004
    Inventors: David J. Madar, Stevan W. Djuric, Melissa J. Michmerhuizen, Hana A. Kopecka, Xiaofeng Li, Kenton L. Longenecker, Zhonghua Pei, Daisy Pireh, Hing L. Sham, Kent D. Stewart, Bruce G. Szczepankiewicz, Paul E. Wiedeman, Hong Yong
  • Publication number: 20040235753
    Abstract: Compounds according to general formula 1, wherein G1 is NR6R7 or a group according to general formula 3 and G2 NR24R25 or a fused polycyclic group are novel. They are selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia, erectile dysfunction.
    Type: Application
    Filed: December 24, 2003
    Publication date: November 25, 2004
    Inventors: Gray Robert William Pitt, Michael Bryan Roe, David Philip Rooker
  • Publication number: 20040235859
    Abstract: The present invention is a chemical compound of formula (I) 1
    Type: Application
    Filed: June 23, 2004
    Publication date: November 25, 2004
    Inventors: David Reginald Adams, Jonathan Mark Bentley, James Edward Paul Davidson, Claire Elizabeth Dawson, Ashley Roger George, Howard Langham Mansell, Patrizio Mattei, Jacques Mizrahi, Matthias Heinrich Nettekoven, Robert Mark Pratt, Stephan Roever, Jonathan Richard Anthony Roffey, Jean-Luc Specklin, Henri Stalder, Kerry Wilkinson
  • Publication number: 20040220171
    Abstract: This invention relates to compounds of formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: November 4, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC
    Inventors: Heinz Pauls, Yong Gong, Julian Levell, Peter Astles, Paul R. Eastwood
  • Patent number: 6812230
    Abstract: This invention is directed to pharmaceutical compositions useful in treating progressive renal fibrosis in mammals comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a non-peptide CCR1 receptor antagonist.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: November 2, 2004
    Assignee: Schering Aktiengesellschaft
    Inventor: Richard Horuk
  • Publication number: 20040209872
    Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
    Type: Application
    Filed: December 23, 2003
    Publication date: October 21, 2004
    Inventors: Terrance P. Snutch, Gerald W. Zamponi, Hassan Pajouhesh, Hossein Pajouhesh, Francesco Belardetti
  • Publication number: 20040209893
    Abstract: The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Inventors: Giuseppe Alvaro, Romano Di Fabio, Riccardo Giovannini, Giuseppe Guercio, Yves St-Denis, Antonella Ursini
  • Publication number: 20040204422
    Abstract: The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula I 1
    Type: Application
    Filed: April 14, 2003
    Publication date: October 14, 2004
    Applicant: Abbott GmbH & Co. KG.
    Inventors: Wilfried M. Braje, Andreas Haupt, Wilfried Lubisch, Roland Grandel, Karla Drescher, Herve Geneste, Liliane Unger, Daryl R. Sauer
  • Publication number: 20040204397
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora, Shikha Vig
  • Publication number: 20040186099
    Abstract: The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them.
    Type: Application
    Filed: March 1, 2004
    Publication date: September 23, 2004
    Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Vijay Kumar Gajubhai Barot
  • Patent number: 6784167
    Abstract: 17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 31, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Jill E. Wood, Jeremy L. Baryza, Catherine R. Brennan, Soongyu Choi, James H. Cook, Brian R. Dixon, Paul P. Ehrlich, David E. Gunn, Ian McAlexander, Peiying Liu, Derek B. Lowe, Anikó M. Redman, William J. Scott, Yamin Wang
  • Publication number: 20040167129
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: December 22, 2003
    Publication date: August 26, 2004
    Inventors: Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Publication number: 20040152697
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: December 3, 2003
    Publication date: August 5, 2004
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Patent number: 6770650
    Abstract: This invention relates to certain cyclic amine derivatives of Formula (I) that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: August 3, 2004
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Leyi Gong, Donald Roy Hirschfeld, Denis John Kertesz, David Bernard Smith, Francisco Xavier Talamas, Robert Stephen Wilhelm
  • Publication number: 20040147511
    Abstract: The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7;R is selected from the group comprising or consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl.
    Type: Application
    Filed: February 23, 2004
    Publication date: July 29, 2004
    Inventors: Matthias Schwarz, Anna Quattropani, Alexander Scheer, Jerome Dorbais, Vincent Pomel
  • Publication number: 20040138206
    Abstract: The present invention relates to a novel sulfonamide derivatives and novel intermediates thereof, preparation thereof, and a pharmaceutical composition comprising the same, and more particularly, to novel sulfonamide derivatives and intermediates thereof that are used as angiogenesis controlling material and that can inhibit overexpression of matrix metalloproteinase that decomposes protein constituents in extracellular and basement membranes of connective tissues, and preparation methods thereof, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: December 11, 2003
    Publication date: July 15, 2004
    Inventors: Yong-Jun Chung, Kyeong-Ho Lee, Youn-Chul Kim, Ho-Jin Park
  • Patent number: 6756378
    Abstract: Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: June 29, 2004
    Assignees: Pharmacopeia Drug Discovery, Inc., Daiichi Pharmaceutical Co., Ltd.
    Inventors: John J. Baldwin, Edward McDonald, Kevin Joseph Moriarty, Christopher Ronald Sarko, Nobuo Machinaga, Atsushi Nakayama, Jun Chiba, Shin Iimura, Yoshiyuki Yoneda
  • Publication number: 20040122019
    Abstract: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit.
    Type: Application
    Filed: December 9, 2003
    Publication date: June 24, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christian Eickmeier, Peter Sieger, Werner Rall, Volkmar Koerner, Rolf Herter
  • Publication number: 20040102450
    Abstract: This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..
    Type: Application
    Filed: July 25, 2003
    Publication date: May 27, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: William R. Ewing, Michael R. Becker, Yong Mi Choi-Sledeski, Heinz W. Pauls, Wei He, Stephen M. Condon, Roderick S. Davis, Barbara A. Hanney, Alfred P. Spada, Christopher J. Burns, John Z. Jiang, Aiwen Li, Michael R. Myers, Wan F. Lau, Gregory B. Poli, Mark A. Bobko, Robert L. Morris, Joseph M. Karpinski, Timothy F. Gallagher, Kent W. Neuenschwander, Robert D. Groneberg, Jean-Francois Sabuco
  • Patent number: 6734183
    Abstract: Compounds of the formula I useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: May 11, 2004
    Assignee: AstraZeneca AB
    Inventors: Christophe B Barlaam, Robert I Dowell, Maurice R V Finlay, Nicholas J Newcombe, Howard Tucker, David Waterson
  • Patent number: 6730678
    Abstract: 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na+/H+ exchange is of therapeutic benefit.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: May 4, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Christian Eickmeier, Peter Sieger, Werner Rall, Volkmar Koerner, Rolf Herter
  • Publication number: 20040072823
    Abstract: The present invention discloses compounds of the formula 1
    Type: Application
    Filed: October 3, 2003
    Publication date: April 15, 2004
    Applicant: Neurosearch A/S
    Inventors: Dan Peters, Gunnar M. Olsen, Simon Feldback Nielsen, Elsebet Ostergard Nielsen
  • Patent number: 6716840
    Abstract: Compounds having the general structure I are provided: X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of and L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r”) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: April 6, 2004
    Assignee: Chiron Corporation
    Inventors: Daniel Chu, Rustum S. Boyce, David Duhl, Bryan H. Chang
  • Publication number: 20040063679
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: September 27, 2002
    Publication date: April 1, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Younes Bekkali, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young, Eugene R. Hickey, Weimin Liu, Usha R. Patel
  • Publication number: 20040048862
    Abstract: The invention relates to piperazine derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. The novel compounds are antagonists of tachykinins, including substance P and other neurokinins.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 11, 2004
    Inventors: Giuseppe Alvaro, Romano Di Fabio, Riccardo Giovannini, Giuseppe Guercio, Yves St-Denis, Antonella Ursini
  • Publication number: 20040044004
    Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
    Type: Application
    Filed: April 8, 2003
    Publication date: March 4, 2004
    Applicant: NeuroMed Technologies, Inc.
    Inventors: Terrance P. Snutch, Gerald W. Zamponi, Hassan Pajouhesh, Hossein Pajouhesh, Francesco Belardetti
  • Publication number: 20040038982
    Abstract: This invention relates to substituted heterocyclic compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, all in mammals, by the use of substituted heterocyclic compounds which are CCR5 receptor antagonists. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD.
    Type: Application
    Filed: February 5, 2003
    Publication date: February 26, 2004
    Inventors: William E. Bondinell, Michael J. Neeb
  • Patent number: 6680321
    Abstract: Compounds of the formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: January 20, 2004
    Assignee: AstraZeneca Canada, Inc.
    Inventors: Edward Roberts, Niklas Plobeck, Claes Wahlestedt
  • Patent number: 6677336
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: January 13, 2004
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Grigory Nudelman, Tim Marquart, Brent K. Blackburn, Venkata P. Palle
  • Publication number: 20040002493
    Abstract: A pharmaceutical composition, which comprises a benzoic acid derivative of formula (I) 1
    Type: Application
    Filed: February 27, 2003
    Publication date: January 1, 2004
    Inventors: Kousuke Tani, Masaki Asada, Kaoru Kobayashi, Masami Narita, Mikio Ogawa
  • Patent number: 6670363
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: December 30, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashwani Kumar Verma, Sudershan K. Arora, Jasbir Singh Arora, Ashok Rattan
  • Publication number: 20030236254
    Abstract: Novel &bgr;-aryl-&agr;-substituted propanoic acids having hypolipidemic and hypocholesteremic activities.
    Type: Application
    Filed: July 19, 2002
    Publication date: December 25, 2003
    Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Vijay Kumar Gajubhai Barot, Saurin Khimshanker Raval, Preeti Saurin Raval, Sujay Basu
  • Publication number: 20030236248
    Abstract: Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and pruritic agents are provided.
    Type: Application
    Filed: June 5, 2003
    Publication date: December 25, 2003
    Inventors: Lawrence I. Kruse, An-Chih Chang, Diane L. DeHaven-Hudkins, John J. Farrar, Forrest Gaul, Virendra Kumar, Michael Anthony Marella, Alan L. Maycock, Wei Yuan Zhang
  • Publication number: 20030236247
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: March 21, 2003
    Publication date: December 25, 2003
    Inventors: Steven W. Elmore, Cheol-Min Park, Xilu Wang
  • Publication number: 20030232807
    Abstract: Novel piperazine and homopiperazine derivatives are agonists of melanocortin receptor(s) and are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of the melanocortin receptors. The compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders such as obesity, diabetes, and sexual dysfunction.
    Type: Application
    Filed: October 4, 2002
    Publication date: December 18, 2003
    Inventors: Graham S. Poindexter, Guanglin Luo, Ling Chen
  • Patent number: 6660741
    Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: where R1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, said R1 further comprising a cyclic or bicyclic structure; R2 is methyl, CH2CH3, (CH2)2CH3, C(CH3)3, phenyl, 3,4-dichiorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH2-(N-Boc-4-piperidine), 4-tetrahydropyran, CH2-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R3 is R2 or C3-8alkyl, R4 is C1-3alkyl; and R5 is NH2, OH, NHOH, NHOCH3, N(CH3)OH, N(CH3)OCH3, NHCH2CH3, NH(CH2CH3), NHCH2(2,4-(OCH3)2Ph, NHCH2(4-NO2)Ph, NHN(CH3)2, proline, or 2-hydroxymethyl pyrrolidine.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: December 9, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borella, David Scheinberg
  • Publication number: 20030225074
    Abstract: Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes.
    Type: Application
    Filed: March 25, 2003
    Publication date: December 4, 2003
    Applicant: The Procter & Gamble Company
    Inventors: Menyan Cheng, Neil Gregory Almstead, Michael George Natchus, Stanislaw Pikul, Biswanath De
  • Publication number: 20030225102
    Abstract: The invention discloses a novel series of compound represented by general formula (I), 1
    Type: Application
    Filed: April 8, 2003
    Publication date: December 4, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20030220324
    Abstract: Selected substituted piperazine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: July 24, 2002
    Publication date: November 27, 2003
    Inventors: Christopher H. Fotsch, Premilla Arasasingham, Yunxin Bo, Ning Chen, Martin H. Goldberg, Nianhe Han, Feng-Yin Hsieh, Michael G. Kelly, Qingyian Liu, Mark H. Norman, Duncan M. Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu
  • Publication number: 20030212066
    Abstract: The present invention is a series of compounds that are derivatives of 1-sulfonyl-pyrrolidine and that demonstrate affinity towards metabotropic glutamate receptors. The invention further relates to medicaments containing these compounds and to a process for their preparation. The compounds possess affinity towards metabotropic glutamate receptors and are therefore useful in the treatment or prevention of acute and/or chronic neurological disorders.
    Type: Application
    Filed: March 26, 2003
    Publication date: November 13, 2003
    Inventors: Vincent Mutel, Juergen Wichmann
  • Publication number: 20030207872
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: January 11, 2002
    Publication date: November 6, 2003
    Applicant: BAYER CORPORATION
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Publication number: 20030203895
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: February 13, 2003
    Publication date: October 30, 2003
    Applicant: Wyeth
    Inventors: Michael Gerard Kelly, Ping Zhou
  • Publication number: 20030199498
    Abstract: The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them.
    Type: Application
    Filed: August 10, 2001
    Publication date: October 23, 2003
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Vijay Kumar Gajubhai Barot
  • Publication number: 20030195203
    Abstract: The invention relates to heterocyclic derivatives of formula (I)
    Type: Application
    Filed: September 27, 2001
    Publication date: October 16, 2003
    Inventors: Andrew Stocker, John Preston, John Wall Rayner, Michael James Smithers, Paul Turner
  • Publication number: 20030176441
    Abstract: The invention provides compounds of Formula (I): 1
    Type: Application
    Filed: November 29, 2002
    Publication date: September 18, 2003
    Inventors: Daisy Joe Du Bois, Denis John Kertesz, Eric Brian Sjogren, David Bernard Smith, Beihan Wang
  • Patent number: 6620815
    Abstract: This invention is directed to oxazolidinone compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: September 16, 2003
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Bharat Lagu, T. G. Murali Dhar, Dhanapalan Nagarathnam, Yoon T. Jeon, Mohammad R. Marzabadi, Wai C. Wong, Charles Gluchowski
  • Patent number: 6617309
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: September 9, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Publication number: 20030162776
    Abstract: The present invention relates to compounds, and prodrugs thereof, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhibit certain proteases of the coagulation cascade.
    Type: Application
    Filed: October 3, 2002
    Publication date: August 28, 2003
    Applicant: Pharmacia Corporation
    Inventors: Michael S. South, Ronald K. Webber, Horng-Chih Huang, Mihaly V. Toth, Alan E. Moormann, Jeffery S. Snyder, Jeffrey A. Scholten, Danny J. Garland, Melvin L. Rueppel, William L. Neumann, Scott Long, Wei Huang, John Trujillo, John J. Parlow, Darin E. Jones, Brenda Case, Michael J. Hayes
  • Publication number: 20030162789
    Abstract: The present invention relates to 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them. More particularly, it relates to 4-hydroxycinnamamide derivatives showing superior antioxidant activity compared to the known antioxidant compounds, their pharmaceutically acceptable salt, and pharmaceutical compositions containing them. It can be usefully used in treating neurodegerative diseases such as aging, cancer, diabetes, ischemic stroke, Parkin's disease, dementia and Huntinton's disease.
    Type: Application
    Filed: November 22, 2002
    Publication date: August 28, 2003
    Inventors: No-Sang Park, Young-Sik Jung, Churl-Min Seong, Hee-Jong Lim, Joong-Ho Yoon, Jae-Yang Kong, Woo-Kyu Park
  • Publication number: 20030158173
    Abstract: A NK1 antagonist having the formula (I), 1
    Type: Application
    Filed: December 17, 2002
    Publication date: August 21, 2003
    Applicant: Schering Corporation
    Inventors: Sunil Paliwal, Gregory A. Reichard, Cheng Wang, Dong Xiao, Hon-Chung Tsui, Neng-Yang Shih, Juan D. Arredondo, Michelle Laci Wrobleski, Anandan Palani